Short Interest in BioVie Inc. (NASDAQ:BIVI) Increases By 36.3%

BioVie Inc. (NASDAQ:BIVI) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 1,840,000 shares, an increase of 36.3% from the November 15th total of 1,350,000 shares. Based on an average daily trading volume, of 5,810,000 shares, the days-to-cover ratio is currently 0.3 days.

BioVie Stock Performance

NASDAQ:BIVI traded up $0.05 during midday trading on Friday, reaching $2.64. 1,850,809 shares of the stock traded hands, compared to its average volume of 1,685,683. The stock has a market capitalization of $46.91 million, a P/E ratio of -0.23 and a beta of 0.40. The company has a fifty day moving average of $2.54 and a 200 day moving average of $1.78. BioVie has a 12 month low of $1.04 and a 12 month high of $33.10.

BioVie (NASDAQ:BIVI) last issued its quarterly earnings data on Monday, September 30th. The company reported ($6.60) EPS for the quarter.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.